Opthotech soars in debut

More from the world of healthcare-related IPOs: Opthotech (OPHT +18%) — they make Fovista, the Phase 3 wet AMD therapy — opens at $23.06 and moves higher.

Fovista is being developed as a combo treatment for use with anti-VEGF agents like Macugen (VRX), and Lucentis (RHHBY.OB, NVS).

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs